We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Rod
Taylor
+44 (0)141 353 7500
Rod.Taylor@glasgow.ac.uk
Mrs
Emma
Burrell
+44 (0)141 330 4744
REACH-HFpEFproject@glasgowctu.org
More information about this study, what is involved and how to take part can be found on the study website.
Exercise-based cardiac rehabilitation in patients with heart failure with preserved ejection fraction (HFpEF).
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Cardiac rehabilitation (CR) is a highly effective and cost-effective treatment for people with heart failure and is the recommended NHS treatment. It improves quality of life and may reduce risk of a hospital admission. However, at present less than one in 20 people in the UK discharged from hospital with diagnosis of heart failure participate in CR. A key reason for this is that people with heart failure find it difficult to get to hospital, and some dislike group formats. With the COVID-19 pandemic, the barrier to accessing hospital based cardiac rehabilitation programmes has become much greater.
Between 2012-18, the trial team co-developed and tested (with people with heart failure, clinicians, and National Health Service (NHS) managers) a home-based CR programme called ‘Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF)’. Through a clinical trial, they were able to confirm that participation in REACH-HF improves quality of life of people with heart failure with reduced ejection fraction (‘HFrEF’) and that it is affordable for the NHS. They now wish to carry out a study to assess that REACH-HF also works for people with heart failure with preserved ejection fraction (‘HFpEF’).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
Current participant exclusion criteria as of 03/04/2024:1. Patients who have undertaken CR within the last 12 months2. Patients who have any contraindications to exercise training (according to local cardiac rehabilitation guidelines)3. Probable alternative diagnoses that in the opinion of the investigator could account for the patient’s HF symptoms (i.e. dyspneoa, fatigue), such as significant pulmonary disease (including primary pulmonary hypertension), anaemia, or obesity. Specifically, patients with the following should be excluded:3.1. Severe pulmonary disease including COPD (i.e. requiring home oxygen, chronic nebulizer therapy, or chronic oral steroid therapy or hospitalised for pulmonary decompensation within 12 months)3.2. Haemoglobin <10 g/dll3.3. BMI >40 kg/m²;4. Patients with prior ejection fraction <45%.5. Patients located in a long-term care home/support setting who are considered to be too frail to engage with the intervention or who are unwilling to travel to research assessments or accommodate home visits.6. Patients who are unable to understand the study information or unable to complete the outcome questionnaires.7. Patients judged to be unable to participate in the study for any other reason (e.g. psychiatric disorder, diagnosis of dementia, life-threatening co-morbidity).
Previous participant exclusion criteria:1. Patients who have undertaken CR within the last 12 months2. Patients who have any contraindications to exercise training3. Patients who have alternative reasons for shortness of breath such as significant pulmonary disease or severe COPD, haemoglobin <10 g/dl, or body mass index (BMI) >40 kg/m²4. Patients with prior ejection fraction <45%5. eGFR <30 ml/min
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mrs
Emma
Burrell
+44 (0)141 330 4744
REACH-HFpEFproject@glasgowctu.org
Prof
Rod
Taylor
+44 (0)141 353 7500
Rod.Taylor@glasgow.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by NHS Greater Glasgow and Clyde and funded by Health Technology Assessment Programme.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
